These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 18355043)
1. Substituents on etoposide that interact with human topoisomerase IIalpha in the binary enzyme-drug complex: contributions to etoposide binding and activity. Bender RP; Jablonksy MJ; Shadid M; Romaine I; Dunlap N; Anklin C; Graves DE; Osheroff N Biochemistry; 2008 Apr; 47(15):4501-9. PubMed ID: 18355043 [TBL] [Abstract][Full Text] [Related]
2. Contributions of the D-Ring to the activity of etoposide against human topoisomerase IIα: potential interactions with DNA in the ternary enzyme--drug--DNA complex. Pitts SL; Jablonksy MJ; Duca M; Dauzonne D; Monneret C; Arimondo PB; Anklin C; Graves DE; Osheroff N Biochemistry; 2011 Jun; 50(22):5058-66. PubMed ID: 21548574 [TBL] [Abstract][Full Text] [Related]
3. Topoisomerase II - drug interaction domains: identification of substituents on etoposide that interact with the enzyme. Wilstermann AM; Bender RP; Godfrey M; Choi S; Anklin C; Berkowitz DB; Osheroff N; Graves DE Biochemistry; 2007 Jul; 46(28):8217-25. PubMed ID: 17580961 [TBL] [Abstract][Full Text] [Related]
4. Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage. Gentry AC; Pitts SL; Jablonsky MJ; Bailly C; Graves DE; Osheroff N Biochemistry; 2011 Apr; 50(15):3240-9. PubMed ID: 21413765 [TBL] [Abstract][Full Text] [Related]
5. DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action. Byl JA; Cline SD; Utsugi T; Kobunai T; Yamada Y; Osheroff N Biochemistry; 2001 Jan; 40(3):712-8. PubMed ID: 11170388 [TBL] [Abstract][Full Text] [Related]
6. Two-Mechanism Model for the Interaction of Etoposide Quinone with Topoisomerase IIα. Gibson EG; King MM; Mercer SL; Deweese JE Chem Res Toxicol; 2016 Sep; 29(9):1541-8. PubMed ID: 27533850 [TBL] [Abstract][Full Text] [Related]
7. Impact of the C-terminal domain of topoisomerase IIalpha on the DNA cleavage activity of the human enzyme. Dickey JS; Osheroff N Biochemistry; 2005 Aug; 44(34):11546-54. PubMed ID: 16114891 [TBL] [Abstract][Full Text] [Related]
8. Catalytic core of human topoisomerase IIα: insights into enzyme-DNA interactions and drug mechanism. Lindsey RH; Pendleton M; Ashley RE; Mercer SL; Deweese JE; Osheroff N Biochemistry; 2014 Oct; 53(41):6595-602. PubMed ID: 25280269 [TBL] [Abstract][Full Text] [Related]
9. Mutation of cysteine residue 455 to alanine in human topoisomerase IIalpha confers hypersensitivity to quinones: enhancing DNA scission by closing the N-terminal protein gate. Bender RP; Osheroff N Chem Res Toxicol; 2007 Jun; 20(6):975-81. PubMed ID: 17516663 [TBL] [Abstract][Full Text] [Related]
10. Polyamine-containing etoposide derivatives as poisons of human type II topoisomerases: Differential effects on topoisomerase IIα and IIβ. Oviatt AA; Kuriappan JA; Minniti E; Vann KR; Onuorah P; Minarini A; De Vivo M; Osheroff N Bioorg Med Chem Lett; 2018 Sep; 28(17):2961-2968. PubMed ID: 30006062 [TBL] [Abstract][Full Text] [Related]
11. Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta. Zhou Z; Zwelling LA; Ganapathi R; Kleinerman ES Br J Cancer; 2001 Sep; 85(5):747-51. PubMed ID: 11531262 [TBL] [Abstract][Full Text] [Related]
12. Hypophosphorylation of topoisomerase IIalpha in etoposide (VP-16)-resistant human carcinoma cell lines associated with carboxy-terminal truncation. Matsumoto Y; Takano H; Kunishio K; Nagao S; Fojo T Jpn J Cancer Res; 2001 Jul; 92(7):799-805. PubMed ID: 11473732 [TBL] [Abstract][Full Text] [Related]
13. Modulation of drug sensitivity in yeast cells by the ATP-binding domain of human DNA topoisomerase IIalpha. Vilain N; Tsai-Pflugfelder M; Benoit A; Gasser SM; Leroy D Nucleic Acids Res; 2003 Oct; 31(19):5714-22. PubMed ID: 14500835 [TBL] [Abstract][Full Text] [Related]
14. The binding modes and binding affinities of epipodophyllotoxin derivatives with human topoisomerase IIα. Naik PK; Dubey A; Soni K; Kumar R; Singh H J Mol Graph Model; 2010 Dec; 29(4):546-64. PubMed ID: 21075653 [TBL] [Abstract][Full Text] [Related]
15. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement. Byl JA; Fortune JM; Burden DA; Nitiss JL; Utsugi T; Yamada Y; Osheroff N Biochemistry; 1999 Nov; 38(47):15573-9. PubMed ID: 10569941 [TBL] [Abstract][Full Text] [Related]
16. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines. Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249 [TBL] [Abstract][Full Text] [Related]
17. A two-drug model for etoposide action against human topoisomerase IIalpha. Bromberg KD; Burgin AB; Osheroff N J Biol Chem; 2003 Feb; 278(9):7406-12. PubMed ID: 12473657 [TBL] [Abstract][Full Text] [Related]
18. Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha. Patel S; Jazrawi E; Creighton AM; Austin CA; Fisher LM Mol Pharmacol; 2000 Sep; 58(3):560-8. PubMed ID: 10953049 [TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of C1-O-substituted-3-(3-butylamino-2-hydroxy-propoxy)-xanthen-9-one as topoisomerase IIα catalytic inhibitors. Park S; Hong E; Kwak SY; Jun KY; Lee ES; Kwon Y; Na Y Eur J Med Chem; 2016 Nov; 123():211-225. PubMed ID: 27484510 [TBL] [Abstract][Full Text] [Related]
20. Benzene metabolites antagonize etoposide-stabilized cleavable complexes of DNA topoisomerase IIalpha. Baker RK; Kurz EU; Pyatt DW; Irons RD; Kroll DJ Blood; 2001 Aug; 98(3):830-3. PubMed ID: 11468185 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]